AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03232372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External-Connection non-submerged Imp
Description: Through a surgical procedure, we will implant implant whit external connection and non submerged to patients.
Study NCT03232372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal Connection Submerged implants
Description: Through a surgical procedure, we will implant implant whit internal connection and submerged to patients.
Study NCT03232372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal Connection non-Submerged Impl
Description: Through a surgical procedure, we will implant implant whit internal connection and non-submerged to patients.
Study NCT00398515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT00398515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00398515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00398515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01677962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Study NCT01677962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell
Study NCT04758260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant
Description: Oral antioxidant oral intake in the 3 months prior to inclusion in the study
Study NCT01386294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
Study NCT01386294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Universal placebo gel
Description: The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
Study NCT00406068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycobacterial cell wall-DNA complex
Description: 8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
Study NCT05352087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is minimally invasive surgery to remove the gallbladder.
Study NCT01049334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
Study NCT01049334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
Study NCT01722474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASI Device
Study NCT03084822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAITH! App digital intervention
Description: The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
Study NCT02326610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human growth hormone,ZOMACTON® (somatropin)
Description: The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
Study NCT02932696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac training program
Description: This program takes place at the Cardiovascular Rehabilitation Department at the Nîmes University Hospital and includes a combination of various physical activities: treadmill, exercise bike, rower, aerobics, gymnastics, serious games, swimming. The program begins approximately within 3 months after myocardial infarction and consists of 20 consecutive days of training. The main physical activity is aerobic interval training (AIT).~30-minute AIT sessions will occur 5x per week for 4 weeks.~1 AIT session includes a warm up for 8 minutes to reach a heart rate during exercise corresponding to 20 to 30% of maximum aerobic power determined during the initial effort test. Then interval training occurs with 4x2 min of high intensity effort (heart rate during exercise corresponding to 80% of maximum aerobic power) alternating with 2 min of active recovery at 20-30% of maximum aerobic power. Then recovery for 8 minutes.
Study NCT02125370 — intervention group
Intervention type: OTHER
Intervention: Qualitative and survey
Study NCT03744715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: Poziotinib
Study NCT01423760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide
Description: Subjects who received tecemotide (L-BLP25) for the treatment of non-small cell lung cancer (NSCLC) or multiple myeloma in a feeder trial will continue to be treated with tecemotide (L-BLP25) and have safety assessments performed until the discontinuation criteria in the respective feeder trial protocol are met.
Study NCT01423760 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Subjects who had not received tecemotide in the feeder study, or who had discontinued treatment with tecemotide (L-BLP25), will only be observed for progressive disease (PD) (if applicable) and survival in 6-month intervals and will not be provided treatment with tecemotide (L-BLP25).
Study NCT01726205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin and normal saline infusion, PRG
Study NCT01375075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally
Study NCT01375075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01375075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT01375075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01375075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally
Study NCT01375075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally
Study NCT02901665 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FCC intervention
Description: Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
Study NCT03417401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg.
Description: Standard 3-port pars plana vitrectomy with surgical stabilizer assisted ( surgical robot) retinal vein cannulation with recombinant tissue Plasminogen Activator (Actilyse-0.25mg/ml) infusion with a maximal dose of 1mg..
Study NCT03417401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion
Description: Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).
Study NCT02101697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Stigma Reduction Intervention
Description: The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.~Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.~Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.~Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.~Our previous research has found that these modules address factors identified as contributing to health professionals' stigma.
Study NCT02101697 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HIV Stigma Reduction Intervention
Description: The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.~Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.~Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.~Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.~Our previous research has found that these modules address factors identified as contributing to health professionals' stigma.
Study NCT01726205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin and ropivacaine 02% infusion
Study NCT01726205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug, normal saline infusion
Study NCT02738723 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 40 Gy for each patient. Patients receiving once-daily therapy ,4 Gy daily in 10 treatments over a period of two weeks.
Study NCT04628377 — intervention group
Intervention type: DEVICE
Intervention: Angiography-drived Index of Microcirculatory Resistance
Description: From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation.
Study NCT04049682 — intervention group
Intervention type: BEHAVIORAL
Intervention: Delayed School Start Time
Description: Francis Parker High School implemented 45-minute later school start time.
Study NCT04392700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300mg
Description: Take the medicine once a day ，300mg/d
Study NCT04392700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir 0.5 mg
Description: Take the medicine once a day，0.5 mg/d
Study NCT01516333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GL 107
Description: Three meals a day
Study NCT01516333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium GL 76
Description: Three meals a day
Study NCT01516333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium GL 68
Description: Three meals a day
Study NCT01516333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GL 48
Description: Three meals a day
Study NCT03498820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia Nociception Index
Description: : Non invasive monitor based on heart rate variability analysis, assessing the parasympathetic nervous activity
Study NCT03498820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: intravenous short-acting opioid routinely administered during general anesthesia
Study NCT02738723 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: 45 Gy for each patient，Accelerated twice-daily thoracic radiotherapy involved the administration of 1.5 Gy in 30 treatments over a period of three weeks.
Study NCT02738723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP
Description: Etoposide 75mg/m2/iv over 90min through day 1 to day 4 and cisplatin 25mg/m2/iv over 30min through day 1 to day 3, repeat Q 3weeks. Continuous administration to six cycles or to disease progression, unacceptable toxicity or patients' refusal.
Study NCT00538083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: 74 grams of single dose solid dark chocolate versus placebo
Study NCT00538083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: 22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
Study NCT00655928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
Study NCT00655928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline 1 litre intravenous over 12 hours pre-operatively
Study NCT01904799 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive Assessment test
Study NCT03072602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study diet
Description: Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
Study NCT03072602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study diet
Description: Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
Study NCT03072602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Challenge
Description: Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
Study NCT03072602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Challenge
Description: Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
Study NCT04108429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare for College Students
Description: Participants will receive access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
Study NCT00546975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resource Support®
Study NCT00546975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resource Protein®
Study NCT00546975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01213030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [F-18] FMISO
Description: 10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
Study NCT01213030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [F-18] HX4
Description: 10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
Study NCT02342834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Small mixed protein and lipid meal
Description: Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
Study NCT00152867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 4mg PO bd for 2 days post chemotherapy
Study NCT00152867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 4mg PO bd for 2 days post chemotherapy
Study NCT02527707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonafarnib
Description: antiviral farnesyltransferase inhibitor
Study NCT02527707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Cytochromes P450 3A4 inhibitor used to boost lonafarnib
Study NCT01569984 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Avastin 7.5 mg/kg IV x 2 doses 14 days apart
Study NCT02113787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacokinetic study
Description: Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days
Study NCT03345056 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: vitrectomy with planned foveal detachment
Description: 23 gauge vitrectomy, posterior hyaloid detachment, internal limiting membrane peeling , sub-macular BSS injection using 38 gauge canula
Study NCT03936387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Erector spinae blocks: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus. Repeated on contralateral side.
Study NCT05662267 — intervention group
Intervention type: OTHER
Intervention: Pancreatic islet transplantation after kidney transplantation
Description: Pancreatic islet transplantation consists in the intrahepatic transplantation of pancreatic islets, as a result of enzymatic digestion of a deceased-donor pancreas.
Study NCT01812902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Study NCT01812902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Study NCT03185689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effectiveness of an intensified DSME in T2D adult patients
Study NCT04153084 — intervention group
Intervention type: DRUG
Intervention: Polyethylene Glycol 4000 with electrolytes
Description: The high volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
Study NCT04153084 — intervention group
Intervention type: DRUG
Intervention: PEG-3350 with electrolytes
Description: The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
Study NCT04153084 — intervention group
Intervention type: DRUG
Intervention: Sodium picosulfate
Description: The Sodium picosulfate will be administered the day before the procedure at different doses depending on the patient´s age:~* From 1 to 2 years old: ¼ sachet reconstituted in ¼ glass of water/juice in the afternoon (15:00 h) and ¼ sachet reconstituted in ¼ glass of water/juice 6 hours later (21:00 h)~* From 2 to 4 years old: ½ sachet in ½ glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* From 4 to 9 years old: 1 sachet in 1 glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* Of 9 years old and older: 1 sachet in the afternoon and 1 sachet at night.
Study NCT01769937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
Study NCT00800215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv SPM 927 and oral placebo tablet
Description: 60-minute infusion iv SPM 927 and oral placebo tablet
Study NCT00800215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral SPM 927 tablet and iv placebo
Description: 60-minute infusion placebo and oral SPM 927 tablet
Study NCT00800215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv SPM 927 and oral placebo tablet
Description: 30-minute infusion iv SPM 927 and oral placebo tablet
Study NCT00800215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral SPM 927 tablet and iv placebo
Description: 30-minute infusion placebo and oral SPM 927 tablet
Study NCT01653730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse 3 portable oxygen concentrator
Study NCT01653730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EverGo portable oxygen concentrator
Study NCT01653730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iGo portable oxygen concentrator
Study NCT00670007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha1- proteinase inhibitor [human]
Description: Lyophilized preparation of 60 mg/kg body weight intravenously once per week
Study NCT01241500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
Study NCT01825902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorine F 18 fluorothymidine
Description: Undergo 18F-FLT PET
Study NCT01825902 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo 18F-FDG PET